Daša Skripová
The current range of oral antidiabetics is enriched by the new class of drugs with completely new and unique mechanism of action. Unlike other antidiabetics, SGLT2 inhibitors block glucose reabsorption in the kidneys, thereby inducing glycosuria. Treatment is effective irrespective of the insulin resistance or insulin deficiency. Safety, efficiency and low risk of hypoglycaemia are favorable properties of SGLT2 inhibitors. Either reduction of body weight or slight antihypertensive effect are the significant benefits seen in SGLT2 inhibitors. The rate of genitourinary tract infections is still the opened question. Together with SGLT2 inhibitors‘ clinical value in the treatment of diabetes mellitus, this question is to be answered in the following years.